ArticleJournal of thoracic disease2025
Correlation of inflammatory markers with progression-free survival in advanced lung cancer patients treated with immune checkpoint inhibitors in combination with chemotherapy: a real-world study.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The impact of β-blockers on outcomes of immune checkpoint inhibitors therapy in advanced lung cancer: a multicenter real-world study.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors (ICIs), principally represented by programmed death 1/programmed death ligand 1 (PD-1/PD-L1) inhibitors have been used in the first-line treatment of advanced lung cancer by Chinese Society of Clinical Oncology (CSCO) since 2018. Biomarkers like PD-L1 and tumor mutational burden (TMB) help to differentiate patients who benefited from ICI therapy. This study aimed to confirm and assess the predictive value of inflammatory markers in advanced lung cancer patients with the treatment of ICIs plus chemotherapy in the real world. The parameters of patients were collected in this retrospective study. Inflammatory markers were mainly calculated at different treatment periods. Hazard ratios (HR) and 95% confidence intervals (CI) were calculated with the univariate and multivariate Cox proportional hazard model. The Cox multivariate regression analysis indicated that a higher eosinophil-to-lymphocyte ratio (ELR) (HR 0.399, 95% CI: 0.189-0.842, P=0.02) and a higher monocyte-to-lymphocyte ratio (MLR) (HR 2.162, 95% CI: 1.116-4.191, P=0.02) at the time of maximizing therapeutic benefits, a higher lactate dehydrogenase (LDH) (HR 2.456, 95% CI: 1.334-4.523, P=0.004) at the time of disease progression were independent risk factors. A higher ELR and a lower MLR at maximizing therapeutic benefits and a lower LDH at disease progression were positive protectors for the progression-free survival (PFS) of advanced lung cancer treated with ICI combined with platinum-based chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.